EC approves AbbVie's upadacitinib as first JAK inhibitor for atopic dermatitis
Unlike the FDA, the European Commission isn’t hesitating before handing marketing authorization to Rinvoq as the first JAK inhibitor to treat moderate and severe atopic dermatitis — eczema — among adults and adolescents. The green light arrived Tuesday morning.
Rinvoq’s approval allows the drug to be marketed and sold in all member states of the European Union, plus a select few other European nations such as Iceland and Norway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.